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Summary.-The production of graft-versus-host (GVH) reactions in (PVGc x Wis-
tar) F1 hybrids by the transfer of PVGc spleen cells resulted in significant resistance
of these recipients to a subsequent challenge with the PVGC leukaemia. Protection
was markedly dependent on dose and timing of allogeneic cell transfer and was
abrogated by irradiation of the cells prior to transfer. GVH activity was shown
to be a prerequisite for induction of the protective effect but was equally effective
when produced by the transfer of Wistar spleen cells in place of PVGC cells.
These points, plus the fact that in vitro investigations ofpossible immune mechan-
isms failed to demonstrate cytotoxic immunity in treated rats, suggested a non-
specific " bystander " effect as the mechanism of protection. The implications
of such a mechanism are discussed.
THE DEMONSTRATIONS of increased
immune responsiveness following allo-
geneic cell interactions (Hamilton, 1973;
Katz, 1972) raised the question whether
GVH reactions could have a similar
effect on immune responses against tu-
mours. Some evidence for this comes
from several reports. Medzihradsky
(1966) showed that the induction of a
GVH reaction in (Lewis x AVN) F1 rats
given the Walker tumour resulted in
prolonged survival times and a decrease
in the number of lethal takes of the
tumour. Similar results were obtained
with a methylcholanthrene-induced tu-
mour when a GVH reaction was induced
simultaneously with tumour inoculation
(Medzihradsky, Konikova and Novotna,
1973).
In guinea-pigs the transfer of allo-
geneic lymphoid cells has been shown
to produce resistance to a subsequent
inoculum of leukaemia cells. This re-
sistance was manifested by striking pro-
longation of survival times and in some
animals which survived indefinitely, re-
sistance to a second chellenge with
leukaemia was demonstrable. The effect
was apparently dependent on a GVH
reaction but attempts to determine the
mechanisms involved were unsuccessful
(Ellman et al., 1972; Katz et al., 1972).
In many of the studies involving anti-
tumour effects produced by the transfer
of allogeneic cells, it has been difficult
to divorce any direct cytotoxic effects
the allogeneic cells may have on the
tumour from the effects of interaction
of allogeneic cells with those of the
host. We have therefore chosen a GVH
model in which the donor and recipient
are histocompatible with the tumour and
where the effects observed can presumably
be attributed solely to the effects of the
allogeneic interaction of lymphoid cells.
We report here our results showing that
interaction of lymphoid cells in a GVH
reaction in these circumstances can result
in marked inhibition ofgrowth of a highly
malignant leukaemia in rats. We have
further characterized the nature of this
anti-tumour activity and present the
results of initial studies designed to
reveal the mechanism of this effect.
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MATERIALS AND METHODS
Animials.-8-10 week old rats of the
inbred PVGC strain were from the MRC
laboratories, Carshalton, Surrey, U.K. Wis-
tar strains and the F1 hybrid of this com-
bination with the PVG, were from the
University of Sydney animal station.
Tumour. The leukaemia used in these
studies was the PVGC lymphoma kindly
supplied by Dr Bruce Roser of the Depart-
ment of Pathology, University of Sydney.
The tumour has a marked leukaemic phase
concurrent with lymph node involvement.
A highly virulent form of this tumour,
obtained by repeated passage in syngeneic
animals, was used in these studies. In this
form only minimal involvement of lymph
nodes is seen and the disease is predominantly
that of a rapidly fatal leukaemia. An i.p.
dose of 104 leukaemic cells was used in all
experiments and produced leukaemia within
about 14 days, and death no longer than
10 days after this. No evidence for re-
sistance on the part of susceptible rats
(PVGC and PVGC hybrids) has yet been
demonstrated (Hersey, 1973a; 1973b).
Tumour cell suspensions were obtained
from the peritoneal cavity of previously i.p.
infected animals by lavage through a wide-
bore perforated needle, with Eagle's minimal
essential medium (MEM) (Microbiological
Assoc., Inc., U.S.A., Cat. No. 12-92) con-
taining Penicillin (100 units/ml) and Strepto-
mycin (100 fig/ml).
To determine the day of onset of leuk-
aemia, sequential blood counts of inoculated
animals were made on a model D Coulter
Counter (Coulter Electronics Ltd., Dunstable,
Beds., England). Rats reaching a count
higher than 30 x 106/ml of whole blood on
two successive days were classed as leukaemic,
since all such rats showed progressive in-
creases in blood count from this point on.
Neonatal induction of tolerance. PVGC
rats less than 24 h old were rendered
neonatally tolerant of (PVGC x Wistar) F1
by the injection of 8 x 107 hybrid bone
marrow cells via the intracardiac route, as
described by Grazer (1958).
Tolerance was assessed by a popliteal
lymph node weight assay, described by
Ford, Burr & Simonsen (1970) for the in
vivo detection of GVH reactivity. In this
assay 5 x 106 lymphoid cells were injected
into the footpads of F1 hybrid rats and
7 days after this, the popliteal lymph nodes
were excised and weighed. Lymphoid cells
from successfully tolerized PVGC rats pro-
duced no increase in node weight while
normal PVGc cells produced a 4- to 5-fold
increase in weight.
In vitro 5'Cr release assays
5tCr labelling of target cells.-Approxi-
mately 3 x 106 tumour cells in 1 ml of MEM
supplemented with 10% Foetal Bovine
Serum (FBS) (Australian Laboratory Ser-
vices, Batch 28) were incubated with 100 ,uCi
of Na2 51CrO4 (Radiochemical Centre, Amer-
sham, Bucks., U.K.) for 2 h at 37°C. The
cells were washed twice in 25 ml of MEM
and resuspended in MEM + 100% FBS
buffered with 20 mM of Hepes.
Antibody-dependent (AD) cell-mediated cy-
totoxicity. Assay of rat sera for this activity
was carried out as previously described
(Hersey, 1973b) using human effector cells
obtained by Hypaque/Ficoll separation of
peripheral blood. 6 x 105 effector cells in
0-2 ml were used in each assay and 2 x 104
target cells were added in 0-2 ml. Test sera
from rats were added in serial concentrations
in duplicate in a volume of 0 05 ml. The
total volume of 0-45 ml was incubated in
capped round-bottomed tubes for 6 h at
37°C. After this the cells were sedimented
by centrifugation and 0 2 ml of each super-
natant was transferred to adjacent tubes
for counting.
Direct cell-mediated cytotoxicity.-Spleen
cells were assayed for direct cytotoxicity
activity after depletion of macrophages by
glass absorption (Hersey, 1973a). Absorbed
spleen cells at concentrations of 3 x 106
1 x 106 and 3 x 105 in 0 5 ml were added
to target cells (2 x 104 in 0 5 ml). Incuba-
tion was for 6 h at 37°C in capped flat-
bottomed tubes. After incubation the cells
w,ere centrifuged and 0 5 ml of supernatant
transferred to adjacent tubes for counting.
All counting was done on a Wallac Gamma
Sample Counter.
Percent 51Cr release was calculated as
follows:
0 51Cr release = x2 x 100 a + bx10
where a = activity in supernatant tube and
b = activity in tube with cell pellet and
remaining supernatant. For the direct cyto-
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toxic assay, the factor was 2 in place of
2-25.
In vitro assay for cytostatic serunt fac-
tors.- Spontaneous 3H-thymidine uptake by
leukaemic cells w-as assessed by short-term
culture of 3 x 106 cells in a volume of
1 ml of Dulbecco's modified Eagle's medium
(DEM), supplemented with 10% FBS, peni-
cillin and streptomycin. Cultures were
pulsed for 4 h with 2 tCi of isotope at
specific activity of 5 Ci/mM (Radiochemical
Centre, Amersham) 2 h after the cultures
were set up. Test and control serum was
added in varying dilutions to these tubes at
the time of dispensing tz determine whether
such sera could produce a decrease in isotope
uptake. Harvesting and counting were car-
ried out by standard trichloroacetic acid
extraction and : scintillation counting pro-
cedures.
Experimiental protocol. Spleen cells w-ere
taken from parental PVGC rats (except
where otherwise indicated) approximately
2 months old, and injected slowly i.v. into
F1 rats 6-8 wAeeks ofage at the times indicated
in the text, in relation to the tumour inoculum
of 104 cells given i.p. on Day 0. Controls
in each experiment were rats given tumour
only or in some experiments rats given tu-
mour and F1 spleen cells at the same doses
as the PVGC spleen cells. Leukaemia onset
wras determined by sequential count of
blood from the tail veins.
IC
E
J
._I
e-
40
20
Statistical analysis. Wilcoxon's two
sample rank test was employed to assess the
significance of variations in the day of
leukaemia onset between groups of 5-6 rats.
Probability levels of 50°0 were chosen as
significant.
Irradiation. Spleen cells were irradiated
by a 60Co source at a distance of 12 inches
in a plane vertical to the beam axis on a
rotating platform. Dose rate was 50 rad/
min.
RESULTS
The protective effect of PVG, spleen
cells.-(Figure 1.) To determine whether
PVGC spleen cells could produce protec-
tion from leukaemia in (PVGC x Wistar)
F1 rats, spleen cells in varying numbers
were transferred i.v. to F1 rats 6 days
before these rats received an i.p. inocula-
tion of 104 tumour cells. The time of
onset of leukaemia in these rats was
determined and compared with that of
a group which had received 108 syngeneic
(F1) cells on Day -6.
Rats pretreated with 3 x 107 or 108
PVGC spleen cells showed significant
delays in leukaemia onset when compared
with the control group (P < 0'01). Re-
cipients of 3 x 108 PYTG, spleen cells
showed no delay in onset.
0
18 20 22 24 26 28 30 32 34 36 56 58 60
Time After Leukaernia Cells Injected (Days)
Fi(e. I. Results show 00f F1 rats in each gIroup with leukaemia on sequential (lays after leuikaemia
inoculation. Grouip I rats receive(d 108 F1 spleen cells on Day -6; groups 2, 3 an(d 4 receivecd
3 x 108, 3 x 107 and 108 PVG-c spleen cells respectively, on Day -6. All rats were inioculated
with 104 leukaermic cells on Day 0.
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= -- 0 and + 6 ani additive protective effect
1 2 . - was noted compared to that of a group
34 .5 receiving spleen cells on Day 6 only
(Groups 2 and 3 in Table I, P < 0.05).
The effect of irradiation (1000 r) of
PVG, spleen cells before transfer. (Table
I.) Using the optimal conditions for
protection, a transfer of 108 PVGC spleen
into F1 hybrids produced a significant
delay in leukaemia onset. When, how-
. ever, such cells were pretreated with
1000 r, no protective effect was observed.
Since it was felt that irradiated cells
might be more rapidly cleared from the
I~< circulation and hence be prejudiced in
14 16 18 20 22 their protective potential, a group of
rats received 3 doses of 108 irradiated
Time After Leukaemia Cells Injected (Days) cells on Days 6, 0 and +-6 (with leuk- aemia challenge on Day 0). This pro-
-F1 rats receivedl 108 PVG, spleen duced a significant delay in onset com-
At varyiig Mt,ervals with respect to
ir inoculation oni Pav 0. Gropl) I pared w,th recipients of leukaemia cells
; 2, Day 21; 3, Day -+6; .5, Day only (P < 0.05). However, the degree 6, Lay 6. Grotup 4 receivedi no of protection achieved with 3 doses of Cul-Ills, irradiated cells was significantly less than
that produced by either I or 3 doses of
dependence of the effect. (Fig. unirradiated cells (P < 001).
effect of variationi in the time The effect of W'istar spleen cells on
ransfer was assessed by transfer leukaemia onset. (Table II.) To test
iform dose of 108 PVGc spleen whether protection was due to immuniza-
, F1 hybrids on Days -21, -14, tion of F1 animals against antigens
r +6, and 104 tumour cells on cross-reacting between PVGc spleen cells
It was found that cells trans- and leukaemia cells (i.e. strain specific),
n Day -6 provided significant Wistar spleen cells were used instead
)n (P < 0.01). All other times of PVGc spleen cells. As shown in
,ansfer were ineffective. Table II, when 108 Wistar spleen cells
ite the demonstration that cell were given on Day 6 in relation to
on Days 0 and +6 were ineffec- the tumour inoculum, a significant delay
en 108 pyQGc spleen cells were in onset of leukaemia was observed
a group of animals on Days 6, (P < 0.01) suiggesting that allogeneic in-
TABLE I. The Effect of Irradiation of Transfused Sjnjencic Donor ('ells on
their Anti-leukae,mic Effect
Fi(. 2.-
cells a
ttimol;
Day a
-14;
spleenl
Tinme
2.) The
of cell t.
of a uni
cells intc
6), 0 o
Day 0.
ferred o]
protectio
of cell tr
Despi
transfers
tive, wh
given to
Grioup
1. T'vnour only
2. 1(8 cells
3. 108 clls x 3*
4. 108 irra(l. cells
5. 108 iira(l. cells x 3*
Dray vof leukaemia
onset
13, 13, 14, 14, 14, 14
16, 16, 16. 17, 17, 18
18, 19, 19. 20, 20, 20t
14, 14, 15, 15, 15, 15
14, 14, 15, 15, 15, 16
IP valii- vs GI).
<0-01
<0-01
N8
<0(05
Oti Days -6, 0, anid 6 in relation to octlutn 104 tumoutr cells, onl Day 0.
t Greater than Group 5 (P < 0 02).
100
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60
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TABLE II. Effect of Transfer ofAllogeneic Donor Cells on Leulcaemia Onset
Grotup
Day of leukaemia
onset
1. Ttumouir only 15, 15, 15, 16, 16
2. 108 Wistar spleein cells Day -6 17, 18, 18, 19, 24, 25
teraction of the cells was responsible for
the effect.
The effect ofF1 spleen cells on leukaemia
onset in PT'G. rats. Since protection was
apparently dependent on an allogeneic
cell interaction it was necessary to assess
whether protection could be provided by
the interaction of Parent and F1 cells
in a HVG situation. When 108 F1
hybrid spleen cells were transferred to
PVG, rats 6 days before leukaemic inocu-
lation there was no significant difference
between the time of leukaemia onset
in these rats and in rats which received
tumour cells only.
The effect of tolerant PVG. spleen
cells. (Figure 3.) The dependence of
protection upon a GVH reaction was
further investigated by assessing the
effect of spleen cells from PVGC rats
which had beeii rendered neonatally
tolerant of(PVGC x Wistar) F1 and shown
to be incapable of inducing a GVH
respon.se in vtro.
100
1 2
.M 80
E
- 60
, 40
20 i
P value 1 vs. 2
<0-01
Rats given 108 tolerant spleen cells
on Day 6 and 104 leukaemia cells on
Day 0, failed to demonstrate a delay in
onset of leukaemia, although 108 normal
cells produced significant delay (P < 0.01).
As a further control in this experiment
a group of rats received 108 " non-
tolerant" cells from PVGC rats in which
tolerance induction had failed and which
were therefore able to produce GVH
reactions in the in vivo GVH assay.
As shown in Fig. 3 recipients of such
cells showed a significant degree of delay,
similar to that produced by normal PVGC
cells.
AD cell-mediated cytotoxicity.-(Figure
4.) Groups of F1 rats were given 108
PVGC spleen cells on Day 6 and serum
samples taken on Days 0, +6 and +12
in relation to the tumour inoculum.
Samples from 3 individual rats were
assayed at these time periods for evidence
of AD cell-mediated cytotoxic activity
and as shown in Fig. 4 no evidence of this
16 48 20 22 24 26 28 30 54 56
Time After Leukaemia Cells Injected (Days)
FriG. 3.-All groups of F1 rats received 104 PVGC leukaemia cells on Day 0. In addition, on Day
-6, group I rats received 108 "tolerant" PVG, spleen cells; group 3, 108 "unsuccessfully tolerized"
PVGC spleen cells (see text); group 4, 108 normal PVGc spleen cells. Group 2 received no
spleen cells.
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(c)
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(d}
0
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lb 5b 250;
Reciprocal Serum Dilutions
FIG. 4. AD cell-mediated cytotoxic activity of sera from F1 rats receiving 108 PVGC spleen cells
on Day -6 and 104 PVG, leukaemia cells on Day 0. Target cells: 51Cr-labelled PVG, leukaemia
cells. Sera at (a) Day 0; (b) Day +6; (c) Day +12; (d) from cytotoxic control (see text). Each
point represents the mean results of 3 different sera assayed in duplicate.
activity was found. Sera from Wistar
rats immunized with 108 PVGc lymphoma
cells were included in the assay as a
positive control and indicate the sensi-
tivity of the assay.
Direct cell-mediated cytotoxicity. (Fig.
5.) Direct cell killing was assessed in
macrophage-depleted spleen populations
from F1 rats treated with 108 PVGc
spleen cells on Day -6. Rats were
sacrificed at Days 0, +6 and + 14 and
their spleens assayed for the presence
of cytotoxic activity against the leuk-
aemia cells. No significant levels of
cytotoxicity were demonstrated at these
times. Graph (d) represents the level
of cytotoxicity developed in Wistar rats
inoculated with PVGc lymphoma 5 days
before assay.
Cytostatic serum factors.-Leukaemic
cells were found to incorporate spon-
taneously a reproducible level of 3H-
thymidine under short-term culture con-
ditions. Sera from experimental rats
were added in varying dilutions to see
whether they could exert an inhibitory
effect on isotope uptake. When the effect
of such sera was compared with the
effect of sera from normal rats, no signi-
ficant depression of isotope uptake could
be demonstrated at any time during the
GVH protocol. It was, however, found
that all sera from normal or test rats
had a markedly inhibitory effect on
isotope uptake by the leukaemic cells.
DISCUSSION
The use of allogeneic lymphoid cells
in immunotherapy of leukaemia has been
reported by several workers (Woodruff
and Nolan, 1963; Mathe et al., 1967;
Boranic, 1968; Britton, 1972; Bortin,
1974). The anti-leukaemia effect in these
studies has generally been regarded as
an example of adoptive immunotherapy,
resulting from histocompatibility differ-
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FIG. 5. Lymphocyte cytotoxicity assay of splenic cells from F, rats ulndergoing GVH pIotocol
and tumour inoculation. Spleens taken at (a) Day 0; (b) Day +6; (c) Day + 14; (d) cyctotoxic
control (see text).
ences between donor lymphoid cells and
the tumour of the recipient. In contra-
distinction, the data presented here de-
monstrate an anti-leukaemic effect in
a GVH reaction in which both donor and
recipient are syngeneic with the leuk-
aemia. The anti-leukaemic effect, in
terms of delay in the time of leukaemia
onset, was equivalent to a 3-4 log reduc-
tion in the size ofthe initial 104 leukaemia
cell inoculum even though both PVGc
and the F1 hybrid are incapable of
rejecting inoculations of very small num-
bers of these tumour cells (Hersey,
1973c).
Over the past few years several
immunological effects of allogeneic cell
interactions have been described, other
than the anti-tumour effects described
here. Increased antibody production
after primary and secondary antigenic
challenge has been described and referred
to as the " allogeneic effect " (Katz, 1972;
Hamilton, 1973). Abrogation of toler-
ance has also been described under
similar conditions by McCullagh (1970).
Similarities of the anti-tumour effect to
these later phenomena are apparent.
The timing of the GVH reaction in
relation to the challenge with tumour
cells or antigen has been found critical
in all studies and coincides with the time
of peak GVH activity. Similarly the
dosage of cells given to the recipients
has also been shown to be important so
that, in our own studies, if the parental
cell inoculum was either too large or
too small the effect was abrogated.
Also, as in our own studies, irradiation
of the donor cells rendered them much
less effective in producing the described
effect suggesting that viable cells capable
of multiplication were needed.
In view of the similarities noted with
these other described effects of allogeneic
cell interactions, the question arises to
what extent they can be implicated in
the anti-tumour effect described in this
model. To answer this question we have
carried out in vitro studies to detect
either direct cell-mediated or AD cell-
mediated immunity. Our failure to find
any evidence of cytotoxic immunity by
the assays argues against specific immune
mechanisms being iinvolved but cannot
be regarded as definitely excluding them.
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The assays used have been shown by
previous studies (Hersey, 1973a, b), and
by the controls used in the present
study to be sensitive in detection of
these meclhanisms after allogeneic im-
munizations but could, nevertheless be
ineffective in the semi-syngeneic model
used here.
Another possible mechanism of the
anti-tumouir effect considered in this study
was that the F1 recipients recognized
antigens on the PVGC spleen cells and
were in effect being immunized against
similar antigens on the PVTGC leukaemia.
Although this contradicts classical trans-
plantation dogma, the concept of ainti-
parental responses receives some support
from the literature (Cudeowicz and Stimp-
fling, 1964; Field, Cauchi and Gibbs,
1967; Ramseier and Lindenmann, 1969).
Several of the experiments described
in this study argue strongly against this
possibility. Firstly it was showin that
PVGC cells tolerant to the F1 recipient
did not give rise to any anti-tumour
effects. As it seems likely that the
tolerant cells have the same antigens as
non-tolerant cells this argues against the
effect being a result of recognition of
parental antigens. Similarly the experi-
ments using irradiated spleen cells can
be interpreted in the same way. Even
when 3 times the dose of irradiated cells
was given the anti-leukaemic effect was
still muich less than that resulting from
a single (lose of unirradiated spleen cells.
Secondly the kineties of the protection
argues against an immunization effect,
in that cells given 14 or 21 days before
could be expected to provide a similar
immunization to that at 6 davs. For
further evidence against this mechanism
the experiment using Wistar spleen cells
can be cited. If immunization against
PVGC spleen cells was involved, then
XVistar spleen cells could be expected
to be less effective than PVGc spleen cells.
This was found not to be the case and
equal protection was afforded by Wistar
spleen cells.
We therefore consider the most likely
explanation for the observed aniti-ttutiour
effect is that it results from non-specific
cytotoxic activity genierate1 durinig the
course ofthe GVH reaction. Non-specific
cytotoxic effects of GVH activity have
been suggested by the in vivo stuidies
of Elkins and Guttman (1968) and
Streilein and Billingham (1970). In vitro
analyses of such effects by Singh, Sabba-
dini and Sehan (1971, 1972) showed that
non-specific cytotoxic effects were gener-
ated 4-8 days after parental cell transfer
and were mediated by host cells. More
receit demonstrations of similar effects
were made by Britton- (1974) who founlfd
evidence of in vitro cytotoxicity against
syngeneic lymphoma cells in nice at the
time of peak GVH activity.
If our interpretation is correct it is
clear that " non-specific " cytotoxic mach-
anisms may play an effective role against
tumour cells in vivo and may underlie
the protective effect seen in several
immunotherapy procedures involving
trainsfer of allogeneic cells. If so, the
measurement of non-specific (ytotoxicity
against tumour cells may be of equal
importance to that of specific immtune
mechanisms in the evaluation of host
resistance to tumours and in theicde-
velopment of immunotherapy procedures.
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University of Sydney Cancer Fulnd. WNe
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